Global Bispecific Antibodies Therapy Blincyto Hemlibra Therapeutics Market Size To Witness 118% Growth To Reach US$ 10 Billion By 2026
- Kuick Research Report Analyzes Clinical & Commercial Opportunity In Global Bispecific Antibodies Market
NEW DELHI, Oct. 7, 2020 /PRNewswire/ --
"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:
- Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
- Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
- Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
- Global Bispecific Antibody Pipeline: 333 Drug
- Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
- Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%
Download Report:
Despite having several hundred clinical success stories of different immunotherapies against solid and advanced cancers, the overall response rate of the patients has reached approximately 50% even when the patients fit completely under all the criteria of treatment. To pave with the clinical failures, researchers have developed and evaluated bispecific therapeutic antibodies, that are combination of two binding specificities leading to improve selectivity as well as efficacy of antibody-based treatment for cancer. The arrival of bispecific antibody for cancer treatment has estimated to be of great potential for wide range of applications in cancer treatment. The current biotherapeutic market for cancer treatment and prevention is estimated to be dominated by antibody drugs, where bispecific antibody represents a novel ally for the next-generation of cancer therapy.
In the past few years, the remarkable progress that has been made with respect to understanding the important hallmarks of the cancer progression and main epitopes involved in it have led to paradigmatic development in the bispecific antibody capable of offering novel promises to the patients who haven't respond to any medical therapy for cancer. The practice of bispecific antibody is not new i.e. this version of cancer therapeutics is a modified version of monoclonal antibody. By observing the increasing incidence of cancer, the management associated with the bispecific antibody has started to develop several strategies important for clinical management of the cancer in the present and in the future.
As per the analysis conducted, it is estimated that the bispecific antibody therapeutics market is growing at a double-digit rate, thus boosting the overall cancer therapeutics market to extreme, especially when compared with other immunotherapies. Further, trends and opportunities coupled within the market i.e. rise in the number of cancer cases, government favorable policies and many others are tending to drive the growth of the market. In our viewpoint, novel alliances developed by major key players of the market and local manufacturers are estimated to be playing important role for delivering tremendous opportunities for the researchers, patients, stakeholders and the payers.
The analysis of the Global bispecific antibody drug market represents that the market is completely focused on providing a better structure to the overall therapeutics market and offer the pharmaceutical industry a broad perspective of an efficient therapy for every cancer type. The research report provides analysis about the assess growth potential of the market by verifying various driving forces, in combination with all the important trends, opportunities and challenges. In addition to it, the research report also provides a long-term outlook for the industry and various other important measures that have helped the market to attract thousands of investors and local drug manufacturers. Lastly, the report also profiles various pharmaceutical companies of the dominating markets that have been boosting the R&D sector of the market.
Table of Contents
1. Introduction to Bispecific Monoclonal Antibody
1.1 Overview of Monoclonal Antibody
1.2 Overview of Bispecific Monoclonal Antibody
1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies
2. The Engineering & Development of Bispecific Antibodies
2.1 Bispecific Antibodies Similar to IgG
2.1.1 Quadroma (Hybrid Hydromas) Approach
2.1.2 "Knobs Into Holes" Approach
2.1.3 CrossMab Approach
2.1.4 Dual-Variable-Domain Immunoglobulin Approach
2.2 Small Bispecific Antibodies
2.2.1 Bispecific Diabodies
2.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)
3. Mechanism Of Action Of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removab®)
3.2 Blinatumomab
4. Applications of Bispecific Antibodies in Diagnostic & Treatment
4.1 BsMAb for Diagnosis of Bacterial & Viral Infectious Diseases
4.2 BsMAb for Cancer Diagnostic
4.3 BsAbs Blocking Signaling Pathways
4.4 BsAbs Targeting Tumor Angiogenesis
4.5 Specific Delivery of Effector Compounds to Targets
4.6 Bispecific Antibodies & Gene Therapy
5. Global Bispecific Antibody Market Outlook
5.1 Current Market Scenario
5.2 Availability of Bispecific Antibodies
5.2.1 Catumaxomab (Removab)
5.2.2 Blinatumomab
5.2.3 Emicizumab
5.2.4 Duligotumab
5.2.5 SAR 156597
6. Approved Bispecific Antibody Dosage & Price Analysis
6.1 Blincyto
6.2 Hemlibra
7. Approved Bispecific Antibody Sales Analysis
7.1 Blincyto
7.2 Hemlibra
8. Global Bispecific Antibodies Clinical Pipeline Overview
8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 Orphan Designated Bispecific Antibodies
9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
10. Marketed Bispecific Antibodies Clinical Insight
10.1 Blinatumomab - Amgen
10.2 Emicizumab - Chugai Pharmaceutical
11. Global Bispecific Antibody Market Dynamics
11.1 Favorable Market Parameters
11.2 Commercialization Challenges
12. Global Bispecific Antibody Market Future Prospects
13. Competitive Landscape
13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi
Contact:
Neeraj Chawla
[email protected]
+91-9810410366
Logo: https://mma.prnewswire.com/media/1245952/Kuick_Research_Logo.jpg
Share this article